{"id":"W2398570616","doi":"10.1158/1078-0432.ccr-16-0506","title":"A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":165,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Drug Research and Development","funders":"Cancer Research UK","keywords":"Glioblastoma; Temozolomide; Immunogenicity; Medicine; Adjuvant; Cancer; Oncology; Clinical trial; Chemoradiotherapy; Internal medicine; Antigen; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006410352,0.0002765325,0.0008627289,0.0008758966,0.0002866178,0.00002509969,0.0008868724,0.0005057383,0.003271201],"category_scores_gemma":[0.001476359,0.0001781144,0.0001672208,0.001173188,0.00133704,0.0001666108,0.0002706656,0.001672637,0.0001660493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004351894,"about_ca_system_score_gemma":0.0009193739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005409571,"about_ca_topic_score_gemma":0.005710073,"domain_scores_codex":[0.993177,0.003034066,0.001324075,0.0007696332,0.0004071078,0.001288142],"domain_scores_gemma":[0.9909185,0.007253884,0.0002173459,0.0008154615,0.000726065,0.00006873534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5779637,0.007280424,0.1296415,0.00004159984,0.0003343003,0.00001629383,0.000582255,0.000005822457,0.2221857,0.00004232906,0.002150199,0.05975587],"study_design_scores_gemma":[0.5512099,0.02113511,0.3680125,0.001536465,0.00002121804,0.000001166823,0.000133549,0.000005073237,0.04002904,0.0001049003,0.01735906,0.0004520928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934242,0.002924365,0.000006694303,0.001065105,0.0003001365,0.002057874,0.0001217054,0.00002069036,0.00007921499],"genre_scores_gemma":[0.9941453,0.001544941,0.000009812501,0.00005950251,0.0001008174,0.0008392883,0.00001479121,0.00005633288,0.003229239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2383709,"threshold_uncertainty_score":0.99764,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1092635865907657,"score_gpt":0.4676425387001081,"score_spread":0.3583789521093425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}